Natural Compounds or Their Derivatives Against Breast Cancer: A Computational Study
Overview
Biotechnology
General Medicine
Authors
Affiliations
Background: Breast cancer is one of the most common types of cancer diagnosed and the second leading cause of death among women. Breast cancer susceptibility proteins of type 1 and 2 are human tumor suppressor genes. Genetic variations/mutations in these two genes lead to overexpression of human breast tumor suppressor genes (e.g., BRCA1, BRCA2), which triggers uncontrolled duplication of cells in humans. In addition, multidrug resistance protein 1 (MDR1), an important cell membrane protein that pumps many foreign substances from cells, is also responsible for developing resistance to cancer chemotherapy. . The aim of this study was to analyze some natural compounds or their derivatives as part of the development of strong inhibitors for breast cancer. . Molecular docking studies were performed using compounds known in the literature to be effective against BRCA1 and BRCA2 and MDR1, with positive control being 5-fluorouracil, an antineoplastic drug as a positive control.
Results: The binding affinity of the compounds was analyzed, and it was observed that they had a better binding affinity for the target proteins than the standard drug 5-fluorouracil. Among the compounds analyzed, -hederin, andrographolide, apigenin, asiatic acid, auricular acid, sinularin, curcumin, citrinin, hispolon, nerol, phytol, retinol palmitate, and sclareol showed the best binding affinity energy to the BRCA1, BRCA2, and MDR1 proteins, respectively.
Conclusions: -Hederin, andrographolide, apigenin, asiatic acid, auricular acid, hispolon, sclareol, curcumin, citrinin, and sinularin or their derivatives can be a good source of anticancer agents in breast cancer.
Natural products as drug leads: exploring their potential in drug discovery and development.
Singh K, Gupta J, Chanchal D, Shinde M, Kumar S, Jain D Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39621089 DOI: 10.1007/s00210-024-03622-6.
Zhu C, Yang Q, Mu X, Zhai Y, Zhao W, Yin Z Cancer Inform. 2024; 23:11769351241300030.
PMID: 39553336 PMC: 11569503. DOI: 10.1177/11769351241300030.
Bala R, Madaan R, Chauhan S, Gupta M, Dubey A, Zahoor I Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(2):703-724.
PMID: 37615709 DOI: 10.1007/s00210-023-02675-3.
Islam M, Martorell M, Gonzalez-Contreras C, Villagran M, Mardones L, Tynybekov B Front Pharmacol. 2023; 14:1099380.
PMID: 37033617 PMC: 10076758. DOI: 10.3389/fphar.2023.1099380.
Anticancer properties of bromelain: State-of-the-art and recent trends.
Pezzani R, Jimenez-Garcia M, Capo X, Sonmez Gurer E, Sharopov F, Lauve Rachel T Front Oncol. 2023; 12:1068778.
PMID: 36698404 PMC: 9869248. DOI: 10.3389/fonc.2022.1068778.